Quick Answer
Minerva Neurosciences, Inc. reported Total Revenue of $41.18 million for fiscal year 2020.
Minerva Neurosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $41.18M |
| Net Income | -$293.42M -20492.7% |
$1.44M +104.8% |
-$30.01M +6.6% |
-$32.11M +35.7% |
-$49.91M -2671.4% |
$1.94M +102.7% |
| Diluted EPS | -$34.67 -18347.4% |
$0.19 +104.1% |
-$4.61 +23.3% |
-$6.01 +35.7% |
-$9.35 -18800.0% |
$0.05 +102.7% |
| Total Assets | $97.97M +163.8% |
$37.14M -34.7% |
$56.90M +3.3% |
$55.09M -28.6% |
$77.12M +33.8% |
$57.63M -25.6% |
| Cash and Equivalents | $82.30M +285.3% |
$21.36M -47.8% |
$40.91M +13.4% |
$36.09M -40.6% |
$60.76M +139.6% |
$25.36M +18.4% |
| Stockholders Equity | -$140.75M -447.8% |
-$25.69M +9.7% |
-$28.46M -42.1% |
-$20.02M -351.1% |
$7.98M -84.9% |
$52.66M +89.6% |
| R&D Expense | $5.76M -51.6% |
$11.90M -6.3% |
$12.71M -13.3% |
$14.65M -54.3% |
$32.04M +45.4% |
$22.04M -62.1% |
| Operating Income | -$15.10M +30.9% |
-$21.85M +5.5% |
-$23.12M +8.4% |
-$25.23M +44.4% |
-$45.37M -2556.5% |
$1.85M +102.4% |
| Shares Outstanding | 43.27M +518.8% |
6.99M +0.0% |
6.99M +31.0% |
5.34M -0.0% |
5.34M -87.5% |
42.72M +9.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2020 | $41.18M | — | — |
| Net Income | September 30, 2025 | -$2.74M | -112.2% | +15.8% |
| Diluted EPS | September 30, 2025 | -$0.36 | -112.1% | +16.3% |
| Total Assets | September 30, 2025 | $28.09M | -34.4% | -7.7% |
| Cash and Equivalents | September 30, 2025 | $12.29M | -53.7% | -19.4% |
| Stockholders Equity | September 30, 2025 | -$34.58M | -59.6% | -7.7% |
| R&D Expense | September 30, 2025 | $925.4K | -51.0% | -28.7% |
| Operating Income | September 30, 2025 | -$2.84M | +34.9% | +15.7% |
| Shares Outstanding | September 30, 2025 | 6.99M | +0.0% | +0.0% |
- Minerva Neurosciences, Inc. reported Total Revenue of $41.18 million for fiscal year 2020.
- Minerva Neurosciences, Inc. reported Net Income of -$293.42 million for fiscal year 2025.
- Minerva Neurosciences, Inc. showed a decrease of -20492.7% in Net Income compared to the prior fiscal year.
- Minerva Neurosciences, Inc. reported Diluted EPS of $34.67 per share (loss) for fiscal year 2025.
- Minerva Neurosciences, Inc. showed a decrease of -18347.4% in Diluted EPS compared to the prior fiscal year.
- Minerva Neurosciences, Inc. reported Total Assets of $97.97 million for fiscal year 2025.
- Minerva Neurosciences, Inc. showed an increase of +163.8% in Total Assets compared to the prior fiscal year.
- Minerva Neurosciences, Inc. reported Cash and Equivalents of $82.30 million for fiscal year 2025.
- Minerva Neurosciences, Inc. showed an increase of +285.3% in Cash and Equivalents compared to the prior fiscal year.
- Minerva Neurosciences, Inc. reported Stockholders Equity of -$140.75 million for fiscal year 2025.
- Minerva Neurosciences, Inc. showed a decrease of -447.8% in Stockholders Equity compared to the prior fiscal year.
- Minerva Neurosciences, Inc. reported R&D Expense of $5.76 million for fiscal year 2025.
- Minerva Neurosciences, Inc. showed a decrease of -51.6% in R&D Expense compared to the prior fiscal year.
- Minerva Neurosciences, Inc. reported Operating Income of -$15.10 million for fiscal year 2025.
- Minerva Neurosciences, Inc. showed an increase of +30.9% in Operating Income compared to the prior fiscal year.
- Minerva Neurosciences, Inc. reported Shares Outstanding of 43.27 million shares for fiscal year 2025.
- Minerva Neurosciences, Inc. showed an increase of +518.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: